Kentaro Nishioka

Mr. Kentaro Nishioka

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2025 in Food Science & Nutrition
Verified
Journal Article
Open access
HOHitoshi Okumura
Hitoshi Okumura
YAYudai Araragi
Yudai Araragi
KNKentaro Nishioka
Kentaro Nishioka
RYReiya Yamashita
Reiya Yamashita
TSToshihide Suzuki
Toshihide Suzuki
NMNorihito Murayama
Norihito Murayama
A four‐week administration of 20 mg/day ergothioneine (EGT), a strong antioxidant, improves sleep quality; however, its effect at lower doses remains unclear. This study estimated the lower effective doses of EGT using a physiologically based pharmacokinetic (PBPK) model in two clinical trials. In Study 1, participants received 5 or 10 mg/day of EGT for 8 weeks, and their plasma and blood EGT concentrations were measured. An optimized PBPK model incorporating absorption, distribution, and excretion was assembled. Our results showed that 8 mg/day of EGT for 16 weeks was optimal for attaining an effective plasma EGT concentration. In Study 2, a randomized, double‐blind, placebo‐controlled study, participants received 8 mg/day EGT or a placebo for 16 weeks. The subjective sleep quality was significantly improved in the EGT group than in the placebo group ( p < 0.05). This is the first study to propose a strategy to estimate lower effective doses based on the PBPK model.

8 January 2025 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
KNKentaro Nishioka
Kentaro Nishioka
TITakahiro Ishimoto
Takahiro Ishimoto
MSMariko Sato
Mariko Sato
RYRuki Yasuda
Ruki Yasuda
YNYumi Nakamura
Yumi Nakamura
NMNorihito Murayama
Norihito Murayama
Introduction: The brain uses ketones, mainly 3-hydroxybutyrate (3-HB), as an alternative energy source. Therefore, oral intake of 3-HB may help maintain brain health. Previous studies indicated that achieving a maximum concentration (Cmax) of 3-HB in plasma at 0.28 mM could initiate ketone metabolism in the brain; we hypothesized that attaining this Cmax would improve brain health.Methods: We aimed to demonstrate the efficacy of an optimized single oral dose of 3-HB on cognitive function and mood through two clinical studies: a pharmacokinetic study and an efficacy study. In the pharmacokinetic study, healthy subjects were ingested 2 and 4 g of 3-HB to construct a compartment model to predict the minimum oral dose of 3-HB needed to achieve the target Cmax. In the efficacy study, a randomized, double-blinded, and placebo-controlled crossover trial, the effects of 3-HB at the predicted doses on cognitive function and mood in healthy subjects were assessed by a serial arithmetic test (SAT), the cognitrax, the profile of mood states 2nd edition (POMS2), and fatigue visual analog scale (VAS).Results: In the pharmacokinetic study, a one-compartment model that includes saturable and non-saturable absorption pathways, constant biosynthesis, and the linear elimination of 3-HB after oral administration were constructed. The model principally reflected the observed serum 3-HB concentrations profiles and predicted a minimum dose of 3.5 g needed to achieve the target Cmax. In the efficacy study, although no significant difference was observed in any cognitive domains assessed by the Cognitrax, total responses and correct answers in the SAT were significantly improved in the active group receiving 3.5 g of 3-HB compared to the placebo group. Regarding the POMS2, confusion–bewilderment, fatigue–inertia, vigor-activity, and total mood disturbance scales were significantly improved in the active group compared to the placebo group. Additionally, fatigue VAS were also significantly improved in the active group compared to the placebo group.Discussion: We successfully established a one-compartment model for oral 3-HB intake and demonstrated partial efficacy on cognitive function and broad efficacy on mood in healthy subjects with a single oral dose of 3.5 g of 3-HB optimized by the model.Clinical trial registration: https://www.umin.ac.jp/ctr/index-j.htm, identifier [UMIN000042095, UMIN000046666].

5 September 2025 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Open access
XMXiangyin Meng
Xiangyin Meng
TOTomoyuki Ohara
Tomoyuki Ohara
KNKentaro Nishioka
Kentaro Nishioka
MSMao Shibata
Mao Shibata
MKMakoto Katsube
Makoto Katsube
TNToshiharu Ninomiya
Toshiharu Ninomiya
Aim: To investigate the association between serum ergothioneine and risk of developing dementia and its subtypes in a community‐dwelling older population. Methods: In this prospective longitudinal analysis of participants enrolled in the Hisayama Study, 1344 Japanese community‐residents aged 65 years and over without dementia at baseline were followed prospectively for a median of 11.2 years (2012–2023). Serum ergothioneine levels were quantified using liquid chromatography–mass spectrometry and divided into quartiles. Cox proportional hazards models were used to estimate the hazard ratios (HRs) and their 95% confidence intervals for the association between serum ergothioneine levels and the risk of dementia subtypes. Results: During the follow‐up, 273 participants developed all‐cause dementia. Among them, 201 had Alzheimer's disease (AD) and 72 had non‐Alzheimer's disease (non‐AD) dementia. The age‐ and sex‐adjusted HRs for all‐cause dementia, AD, and non‐AD dementia decreased progressively across increasing quartiles of serum ergothioneine (all P for trend <0.05). These associations remained significant after adjustment for a wide range of cardiovascular, lifestyle, and dietary factors, including daily vegetable intake ( P for trend <0.05). In subgroup analyses stratified by daily vegetable intake, higher serum ergothioneine levels were consistently associated with lower dementia risk, irrespective of vegetable consumption. Conclusions: Our findings showed that higher serum ergothioneine levels were associated with a lower risk of developing all‐cause dementia, AD, and non‐AD dementia in an older Japanese population. Since ergothioneine cannot be synthesized in the human body, a diet rich in ergothioneine may be beneficial in reducing the risk of dementia.

17 March 2025 in Molecules
Verified
Journal Article
Open access
PDF file
HFHidetoshi Fujii
Hidetoshi Fujii
MIMoeno Ito
Moeno Ito
KNKentaro Nishioka
Kentaro Nishioka
KNKatsutoshi Nishino
Katsutoshi Nishino
TOTakanao Otsuka
Takanao Otsuka
MNMasaya Nagao
Masaya Nagao
Tryptase, which is abundant in human mast cells and is involved in allergic inflammations such as asthma, is a serine protease. We isolated a tryptase inhibitor, procyanidin B8 3,3′-di-O-gallate (PB8GG’), a tannin, from the methanol extract of rhubarb (RHEI RHIDOMA), which is a traditional Chinese medicine (Kampo medicine in Japan). Since it did not inhibit another serine protease trypsin, PB8GG’ specifically inhibited tryptase. A standard kinetic analysis of the inhibitory fashion of PB8GG’ against tryptase suggested that PB8GG’ inhibited tryptase in an allosteric manner. We searched for other tannins like PB8GG’ expected to bind tryptase using AutoDock vina. Two ellagitannins, carpinins B and E, isolated from young leaves of Carpinus japonica were selected as candidates of tryptase inhibitors. Carpinins B and E themselves had almost no inhibitory activity against tryptase but enhanced the inhibitory activity of PB8GG’ against tryptase. This is an example that shows that a combination of an allosteric inhibitor with other compounds that bind but have no inhibitory activity can be used to develop a clinically useful combinatorial enzyme inhibitor.